NO20053953L - Polymorfe former av {6,7-Bis(2-metoksy-etoksy) kinazolin-4-yl}-3(3e) - Google Patents

Polymorfe former av {6,7-Bis(2-metoksy-etoksy) kinazolin-4-yl}-3(3e)

Info

Publication number
NO20053953L
NO20053953L NO20053953A NO20053953A NO20053953L NO 20053953 L NO20053953 L NO 20053953L NO 20053953 A NO20053953 A NO 20053953A NO 20053953 A NO20053953 A NO 20053953A NO 20053953 L NO20053953 L NO 20053953L
Authority
NO
Norway
Prior art keywords
quinazolin
bis
ethynyl
ethoxy
methoxy
Prior art date
Application number
NO20053953A
Other languages
English (en)
Other versions
NO330781B1 (no
Inventor
Andre Gerard Bubendorf
Michael Hennig
Pirmin Hidber
Goesta Rimmler
Franziska Rohrer
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32842701&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20053953(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20053953L publication Critical patent/NO20053953L/no
Publication of NO330781B1 publication Critical patent/NO330781B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20053953A 2003-02-17 2005-08-25 Polymorfe former av {6,7-Bis(2-metoksy-etoksy) kinazolin-4-yl(3-etynyl-fenyl)aminhydroklorid, fremgangsmate for fremstilling av slike, farmasoytisk preparat omfattende slike, slike forbindelser for anvendelse som medikament samt slike forbindelser for behandling av sykdommer NO330781B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03003587 2003-02-17
PCT/EP2004/001244 WO2004072049A1 (en) 2003-02-17 2004-02-11 Polymorph of {6,7-bis(2-methoxy-ethoxy)-quinazolin-4-yl}-(3e)

Publications (2)

Publication Number Publication Date
NO20053953L true NO20053953L (no) 2005-08-31
NO330781B1 NO330781B1 (no) 2011-07-18

Family

ID=32842701

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053953A NO330781B1 (no) 2003-02-17 2005-08-25 Polymorfe former av {6,7-Bis(2-metoksy-etoksy) kinazolin-4-yl(3-etynyl-fenyl)aminhydroklorid, fremgangsmate for fremstilling av slike, farmasoytisk preparat omfattende slike, slike forbindelser for anvendelse som medikament samt slike forbindelser for behandling av sykdommer

Country Status (24)

Country Link
US (1) US7148231B2 (no)
EP (1) EP1597239B2 (no)
JP (1) JP4456079B2 (no)
KR (1) KR100797430B1 (no)
CN (1) CN100506803C (no)
AT (1) ATE408605T1 (no)
AU (1) AU2004212067C1 (no)
BR (1) BRPI0407520A (no)
CA (1) CA2514977C (no)
CO (1) CO5601019A2 (no)
DE (1) DE602004016628D1 (no)
DK (1) DK1597239T4 (no)
ES (1) ES2314373T5 (no)
HR (1) HRP20050707B1 (no)
IL (1) IL169975A (no)
MX (1) MXPA05008598A (no)
NO (1) NO330781B1 (no)
NZ (1) NZ541500A (no)
PL (1) PL225428B1 (no)
PT (1) PT1597239E (no)
RU (1) RU2376294C2 (no)
SI (1) SI1597239T2 (no)
WO (1) WO2004072049A1 (no)
ZA (1) ZA200506339B (no)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US7625911B2 (en) * 2005-01-12 2009-12-01 Mai De Ltd. Amorphous form of erlotinib hydrochloride and its solid amorphous dispersion
PL2032521T3 (pl) * 2006-06-27 2010-05-31 Sandoz Ag Nowy sposób wytwarzania soli
EP2054393A1 (en) 2006-07-28 2009-05-06 Synthon B.V. Crystalline erlotinib
US8372856B2 (en) 2006-10-27 2013-02-12 Synthon Bv Hydrates of erlotinib hydrochloride
KR20100014512A (ko) 2007-02-21 2010-02-10 낫코 파마 리미티드 엘로티닙 하이드로클로라이드의 신규한 다형체 및 제조방법
KR101441930B1 (ko) * 2007-04-04 2014-09-19 시플라 리미티드 에르로티닙 및 그의 약학적으로 허용가능한 염의 제조방법
EP2218713A1 (en) 2007-08-17 2010-08-18 Hetero Drugs Limited Erlotinib hydrochloride polymorph Form A substantially free of polymorph Form B
US20090124642A1 (en) * 2007-08-23 2009-05-14 Augusto Canavesi Crystalline forms of Erlotinib HCI and formulations thereof
EP2181099A2 (en) * 2007-08-23 2010-05-05 Plus Chemicals S.A. Crystalline forms of erlotinib hcl and formulations thereof
US20100004449A1 (en) * 2008-07-07 2010-01-07 Plus Chemicals Sa Crystalline forms of erlotinib base and erlotinib hcl
WO2010040212A1 (en) * 2008-10-08 2010-04-15 Apotex Pharmachem Inc. Processes for the preparation of erlotinib hydrochloride
EP2213281A1 (en) 2009-02-02 2010-08-04 Ratiopharm GmbH Pharmaceutical composition comprising N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
CN102438995B (zh) 2009-03-26 2014-12-17 兰贝克赛实验室有限公司 厄洛替尼或其药学上可接受的盐的制备工艺
WO2011058525A2 (en) 2009-11-12 2011-05-19 Ranbaxy Laboratories Limited Processes for the preparation of erlotinib hydrochloride form a and erlotinib hydrochloride form b
CN101987834B (zh) * 2010-06-13 2012-07-18 信泰制药（苏州）有限公司 一种结晶形态的盐酸埃罗替尼及其制备方法
AU2011298167B2 (en) 2010-07-23 2015-11-26 Generics [Uk] Limited Pure erlotinib
WO2012150606A2 (en) 2011-05-03 2012-11-08 Cadila Healthcare Limited A process for preparing stable polymophic form of erlotinib hydrochloride
NZ630289A (en) 2012-09-04 2016-08-26 Shilpa Medicare Ltd Crystalline erlotinib hydrochloride process
WO2014118737A1 (en) 2013-01-31 2014-08-07 Ranbaxy Laboratories Limited Erlotinib salts
CN103333124B (zh) * 2013-05-28 2015-03-25 埃斯特维华义制药有限公司 一种制备盐酸厄洛替尼晶型f的方法
WO2016082879A1 (en) * 2014-11-27 2016-06-02 Synthon B.V. Pharmaceutical composition comprising erlotinib hydrochloride
RU2610337C1 (ru) * 2015-12-10 2017-02-09 Индивидуальный предприниматель Михайлов Олег Ростиславович Кристаллическая β-модификация N-(3-этинилфенил)-6,7-бис(2 метоксиэтокси)хиназолин-4-амин гидрохлорида, способ её получения и фармацевтическая композиция на её основе
JP2019059685A (ja) * 2017-09-26 2019-04-18 日本化薬株式会社 エルロチニブを有効成分とする医薬錠剤
JP2020090456A (ja) * 2018-12-05 2020-06-11 日本化薬株式会社 エルロチニブを有効成分とする医薬錠剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6434574A (en) * 1987-07-30 1989-02-06 Mazda Motor Full mold casting device
CA2216796C (en) 1995-03-30 2003-09-02 Pfizer Inc. Quinazoline derivatives
US5747498A (en) † 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
ES2238825T3 (es) 1998-04-29 2005-09-01 Osi Pharmaceuticals, Inc. Mesilato de n-(3-etinilfenilamino)-6,7-bis(2-metoxietoxi)-4-quinazolinamina anhidro y monohidrato.
RS49836B (sr) 1999-03-31 2008-08-07 Pfizer Products Inc., Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування

Also Published As

Publication number Publication date
SI1597239T2 (sl) 2022-10-28
PL378561A1 (pl) 2006-05-02
BRPI0407520A (pt) 2006-02-14
US20040162300A1 (en) 2004-08-19
HRP20050707B1 (hr) 2013-10-25
NZ541500A (en) 2008-03-28
KR20050095898A (ko) 2005-10-04
AU2004212067B2 (en) 2009-03-19
HRP20050707A2 (en) 2006-07-31
ES2314373T3 (es) 2009-03-16
IL169975A (en) 2011-06-30
WO2004072049A1 (en) 2004-08-26
CA2514977A1 (en) 2004-08-26
PL225428B1 (pl) 2017-04-28
US7148231B2 (en) 2006-12-12
EP1597239B2 (en) 2022-07-20
ES2314373T5 (es) 2022-10-11
CN1751032A (zh) 2006-03-22
ZA200506339B (en) 2006-05-31
DK1597239T4 (da) 2022-09-26
SI1597239T1 (sl) 2009-02-28
JP4456079B2 (ja) 2010-04-28
RU2376294C2 (ru) 2009-12-20
RU2005128774A (ru) 2006-05-10
AU2004212067C1 (en) 2009-09-24
MXPA05008598A (es) 2005-11-04
PT1597239E (pt) 2008-10-10
CN100506803C (zh) 2009-07-01
CO5601019A2 (es) 2006-01-31
AU2004212067A1 (en) 2004-08-26
NO330781B1 (no) 2011-07-18
EP1597239A1 (en) 2005-11-23
DK1597239T3 (da) 2008-12-08
ATE408605T1 (de) 2008-10-15
JP2006521288A (ja) 2006-09-21
KR100797430B1 (ko) 2008-01-23
CA2514977C (en) 2010-06-22
DE602004016628D1 (de) 2008-10-30
EP1597239B1 (en) 2008-09-17

Similar Documents

Publication Publication Date Title
NO20053953L (no) Polymorfe former av {6,7-Bis(2-metoksy-etoksy) kinazolin-4-yl}-3(3e)
HRP20020388B1 (hr) Postojan polimorfni oblik n-(3-etinilfenilamino)-6,7-bis(2-metoksietoksi)-4-kinazolinamin hidroklorida: metode njegova dobivanja i uporaba
UA84167C2 (ru) Производные хиназолина как ингибиторы тирозинкиназы, способ их получения (варианты), фармацевтическая композиция на их основе
ATE419253T1 (de) Inhibitoren von thienopyridin- und furopyridinkinase
UA85394C2 (ru) Замещенные хинолины в качестве ингибиторов ферментов протеинтирозиновых киназ
ATE554087T1 (de) Neue kinaseinhibitoren
YU66100A (sh) N-(3-etinilfenilamino)-6,7-bis(2-metoksietoksi)-4- hinazolinamin mezilat, bezvodni i monohidrat
TW200634012A (en) 3-amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents
UA85698C2 (ru) Хинолиновые промежуточные соединения для синтеза ингибиторов рецепторной тирозинкиназы и способ их получения
DE602004011924D1 (de) Chinazoline derivate und ihre anwendung in der krebsbehandlung
NO20051104L (no) Fremgangsmate for fremstilling av 4-(3'-klor-4'-fluoranilino)-7-metoksy-6-(3-morfolinpro poksy)quinazolin
WO2004030620A3 (en) Novel tyrosine kinase inhibitors
BRPI0615272A2 (pt) inibidores de p38 map kinase e métodos para uso dos mesmos
MXPA05013076A (es) Compuestos de isoindolina-1-ona como inhibidores de cinasa.
BR0214582A (pt) Derivados de piperazina para uso como antagonista do receptor ccr-3 no tratamento de asma
BR0214611A (pt) Antagonistas vii de receptor ccr-3